

### Product Information

**Size:**

50ul

**Reactivity:**

Human, Mouse, Rat

**Source:**

Rabbit

**Isotype:**

IgG

**Applications:**

ELISA, IHC

**Recommended dilutions:**

ELISA:1:2000-1:5000, IHC:1:50-1:200

**Protein Background:**

Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro, in the presence or in the absence of BRCA1-BARD1 E3 ubiquitin-protein ligase complex, catalyzes the synthesis of 'Lys-48'-linked polyubiquitin chains. Does not transfer ubiquitin directly to but elongates monoubiquitinated substrate protein. Mediates the selective degradation of short-lived and abnormal proteins, such as the endoplasmic reticulum-associated degradation (ERAD) of misfolded luminal proteins. Ubiquitinates huntingtin. May mediate foam cell formation by the suppression of apoptosis of lipid-bearing macrophages through ubiquitination and subsequent degradation of p53/TP53. Proposed to be involved in ubiquitination and proteolytic processing of NF-kappa-B; in vitro supports ubiquitination of NFKB1. In case of infection by cytomegaloviruses may be involved in the US11-dependent degradation of MHC class I heavy chains following their export from the ER to the cytosol.

**Gene ID:**

AP1B1

**Uniprot**

Q10567

**Synonyms:**

adaptor-related protein complex 1, beta 1 subunit

**Immunogen:**


Synthetic peptide of human AP1B1.

**Storage:**


-20°C; C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol

## Product Images

---



The image on the left is immunohistochemistry of paraffin-embedded Human lung cancer tissue using PACO191111(AP1B1 Antibody) at dilution 1/70, on the right is treated with synthetic peptide. (Original magnification: x—200).



The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using PACO191111(AP1B1 Antibody) at dilution 1/70, on the right is treated with synthetic peptide. (Original magnification: x—200).